HC Wainwright restated their buy rating on shares of Aytu Bioscience Inc (NASDAQ:AYTU) in a research report sent to investors on Thursday morning. The firm currently has a $9.00 target price on the stock.

Separately, Rodman & Renshaw assumed coverage on shares of Aytu Bioscience in a report on Monday, September 26th. They set a buy rating and a $9.00 price target on the stock.

Aytu Bioscience (NASDAQ:AYTU) opened at 3.03 on Thursday. The company’s market cap is $15.36 million. The firm’s 50-day moving average price is $3.59 and its 200-day moving average price is $4.70. Aytu Bioscience has a 12-month low of $3.01 and a 12-month high of $57.00.

Aytu Bioscience Company Profile

Aytu Bioscience, Inc, formerly Rosewind Corporation, is a healthcare company. The Company is focused on developing treatments for urological and related conditions. The Company’s pipeline of products includes Zertane, and Zertane and a phosphodiesterase type 5 (PDE-5). The Company is conducting Phase III clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated for the treatment of premature ejaculation (PE).

5 Day Chart for NASDAQ:AYTU

Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.